The role of immunomodulatory medications in the treatment of COVID-19.
Curr Opin Rheumatol
; 33(5): 431-445, 2021 09 01.
Article
in English
| MEDLINE | ID: covidwho-2279944
ABSTRACT
PURPOSE OF REVIEW Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. RECENT FINDINGS:
Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations.SUMMARY:
Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Curr Opin Rheumatol
Journal subject:
Rheumatology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS